Palladino-Davis Anna G, Davis Christopher S
Department of Preventive Medicine, Northwestern University, Chicago, IL, USA.
Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Cardiol Young. 2020 Jun;30(6):799-806. doi: 10.1017/S1047951120001146. Epub 2020 May 20.
Pulmonary vascular disease resulting from CHDs may be the most preventable cause of pulmonary artery hypertension worldwide. Many children in developing countries still do not have access to early closure of clinically significant defects, and the long-term outcomes after corrective surgery remain unclear. Focused on long-term results after isolated ventricular septal defect repair, our review sought to determine the most effective medical therapy for the pre-operative management of elevated left-to-right shunts in patients with an isolated ventricular septal defect.
We identified articles specific to the surgical repair of isolated ventricular septal defects. Specific parameters included the pathophysiology and pre-operative medical management of pulmonary over-circulation and outcomes.
Studies most commonly focused on histologic changes to the pulmonary vasculature and levels of thromboxanes, prostaglandins, nitric oxide, endothelin, and matrix metalloproteinases. Only 2/44 studies mentioned targeted pharmacologic management to any of these systems related to ventricular septal defect repair; no study offered evidence-based guidelines to manage pulmonary over-circulation with ventricular septal defects. Most studies with long-term data indicated a measurable frequency of pulmonary artery hypertension or diminished exercise capacity late after ventricular septal defect repair.
Long-term pulmonary vascular and respiratory changes can occur in children after ventricular septal defect repair. Research should be directed at providing an evidenced-based approach to the medical management of infants and children with ventricular septal defects (and naturally all CHDs) to minimise consequences of pulmonary artery hypertension, particularly as defect repair may occur late in underprivileged societies.
先天性心脏病导致的肺血管疾病可能是全球肺动脉高压最可预防的病因。发展中国家的许多儿童仍无法早期闭合具有临床意义的缺损,而且矫正手术后的长期预后仍不明确。聚焦于孤立性室间隔缺损修补术后的长期结果,我们的综述旨在确定对孤立性室间隔缺损患者术前管理左向右分流增加的最有效药物治疗方法。
我们确定了特定于孤立性室间隔缺损手术修补的文章。具体参数包括肺循环过度的病理生理学和术前药物管理以及预后。
研究最常关注肺血管系统的组织学变化以及血栓烷、前列腺素、一氧化氮、内皮素和基质金属蛋白酶的水平。44项研究中只有2项提到了针对与室间隔缺损修补相关的任何这些系统的靶向药物管理;没有研究提供基于证据的指南来管理室间隔缺损导致的肺循环过度。大多数有长期数据的研究表明,室间隔缺损修补术后晚期肺动脉高压的发生率可测或运动能力下降。
室间隔缺损修补术后儿童可能会出现长期肺血管和呼吸变化。研究应致力于为室间隔缺损(以及所有先天性心脏病)患儿的药物管理提供基于证据的方法,以尽量减少肺动脉高压的后果,特别是在贫困地区缺损修补可能较晚进行的情况下。